Hendricks Diane - 16 Dec 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: 10%+ Owner
Issuer ticker: MNPR
Reported as of: 16 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Dec 2025, 15:42:31 UTC
Source filing: View source filing
Reporting owner signature: /s/ Quan Vu, Attorney-in-fact

Key filing fact

Hendricks Diane filed Form 4 for Monopar Therapeutics (MNPR) on 17 Dec 2025.

Key facts

This page summarizes Hendricks Diane's Form 4 filing for Monopar Therapeutics (MNPR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Dec 2025, 15:42.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001727478 Primary reporting owner

Hendricks Diane

Relationship: 10%+ Owner
Address: 1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature: /s/ Quan Vu, Attorney-in-fact
Signature date: 17 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNPR transaction

Common Stock

Other

Transaction value: $0
Shares: -43,499
Change %: -7.1%
Price: $0.000000
Shares after: 567,580
Date: 16 Dec 2025
Ownership: See footnote
Footnotes: F1

MNPR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 93,750
Date: 16 Dec 2025
Ownership: See footnote
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Hendricks Diane is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Reported disposition relates to pro rata distribution by Gem Pharmaceuticals, LLC ("Gem") to its members in which the reporting person has no pecuniary interest. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and the reporting person, a manager of Gem, owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein.

Footnote F2

This is based upon the 93,750 shares of Monopar Common Stock that DMH Business LLC directly owns. As a manager of DMH Business LLC, Ms. Hendricks may be deemed to share voting and dispositive power over these 93,750 shares. Ms. Hendricks disclaims beneficial ownership of the 93,750 shares held by DMH Business LLC, except to the extent of her pecuniary interest therein.